Functional outcomes in adult patients with herpes simplex encephalitis admitted to the ICU: a multicenter cohort study.


Journal

Intensive care medicine
ISSN: 1432-1238
Titre abrégé: Intensive Care Med
Pays: United States
ID NLM: 7704851

Informations de publication

Date de publication:
08 2019
Historique:
received: 16 04 2019
accepted: 27 06 2019
pubmed: 12 7 2019
medline: 21 4 2020
entrez: 12 7 2019
Statut: ppublish

Résumé

We aimed to study the association of body temperature and other admission factors with outcomes of herpes simplex encephalitis (HSE) adult patients requiring ICU admission. We conducted a retrospective multicenter study on patients diagnosed with HSE in 47 ICUs in France, between 2007 and 2017. Fever was defined as a body temperature higher or equal to 38.3 °C. Multivariate logistic regression analysis was used to identify factors associated with poor outcome at 90 days, defined by a score of 3-6 (indicating moderate-to-severe disability or death) on the modified Rankin scale. Overall, 259 patients with a score on the Glasgow coma scale of 9 (6-12) and a body temperature of 38.7 (38.1-39.2) °C at admission were studied. At 90 days, 185 (71%) patients had a poor outcome, including 44 (17%) deaths. After adjusting for age, fever (OR = 2.21; 95% CI 1.18-4.16), mechanical ventilation (OR = 2.21; 95% CI 1.21-4.03), and MRI brain lesions > 3 lobes (OR = 3.04; 95% CI 1.35-6.81) were independently associated with poor outcome. By contrast, a direct ICU admission, as compared to initial admission to the hospital wards (i.e., indirect ICU admission), was protective (OR = 0.52; 95% CI 0.28-0.95). Sensitivity analyses performed after adjustment for functional status before admission and reason for ICU admission yielded similar results. In HSE adult patients requiring ICU admission, several admission factors are associated with an increased risk of poor functional outcome. The identification of potentially modifiable factors, namely, elevated admission body temperature and indirect ICU admission, provides an opportunity for testing further intervention strategies.

Identifiants

pubmed: 31292686
doi: 10.1007/s00134-019-05684-0
pii: 10.1007/s00134-019-05684-0
doi:

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

1103-1111

Commentaires et corrections

Type : ErratumIn

Références

Stroke. 2011 Aug;42(8):2276-9
pubmed: 21680905
Medicine (Baltimore). 2016 Jul;95(30):e4092
pubmed: 27472682
Neurol Sci. 2013 Oct;34(10):1879-81
pubmed: 23780666
Med Mal Infect. 2017 May;47(3):179-194
pubmed: 28412044
Crit Care. 2015 Sep 21;19:345
pubmed: 26387515
J Neurol. 2017 Jun;264(6):1204-1208
pubmed: 28516331
N Engl J Med. 2004 Oct 28;351(18):1849-59
pubmed: 15509818
Epidemiol Infect. 2012 Feb;140(2):372-81
pubmed: 21470440
Clin Infect Dis. 2002 Aug 1;35(3):254-60
pubmed: 12115090
Stroke. 1988 May;19(5):604-7
pubmed: 3363593
Stroke. 2010 May;41(5):1048-50
pubmed: 20224060
Neurology. 2012 Nov 20;79(21):2125-32
pubmed: 23136265
Clin Infect Dis. 2012 May;54(10):1455-64
pubmed: 22460967
J Neurol. 2016 Feb;263(2):277-289
pubmed: 26568560
Clin Microbiol Infect. 2009 Jun;15(6):560-4
pubmed: 19392906
N Engl J Med. 1977 Aug 11;297(6):289-94
pubmed: 195208
Crit Care Med. 1981 Aug;9(8):591-7
pubmed: 7261642
Crit Care Med. 2008 Apr;36(4):1330-49
pubmed: 18379262
Clin Infect Dis. 2013 Oct;57(8):1114-28
pubmed: 23861361
BMC Infect Dis. 2012 Dec 18;12:356
pubmed: 23245564
Intensive Care Med. 2015 Feb;41(2):318-21
pubmed: 25398306
Neurology. 2013 Aug 27;81(9):793-800
pubmed: 23892708
Clin Microbiol Infect. 2016 Jun;22(6):568.e9-568.e17
pubmed: 27085724
Intensive Care Med. 2015 May;41(5):823-32
pubmed: 25643903
Intensive Care Med. 1996 Jul;22(7):707-10
pubmed: 8844239
Clin Infect Dis. 2015 May 1;60(9):1377-83
pubmed: 25637586
JAMA. 1993 Dec 22-29;270(24):2957-63
pubmed: 8254858
Eur J Neurol. 2015 Jan;22(1):6-16, e1
pubmed: 25174376
J Clin Virol. 2014 Jun;60(2):112-8
pubmed: 24768322
Lancet Infect Dis. 2010 Dec;10(12):835-44
pubmed: 20952256

Auteurs

P Jaquet (P)

Department of Intensive Care Medicine and Infectious Diseases, Bichat-Claude Bernard University Hospital, AP-HP, 46 Rue Henri Huchard, 75877, Paris Cedex, France.

E de Montmollin (E)

Department of Intensive Care Medicine and Infectious Diseases, Bichat-Claude Bernard University Hospital, AP-HP, 46 Rue Henri Huchard, 75877, Paris Cedex, France.
UMR 1137, IAME, Paris Diderot University, Paris, France.

C Dupuis (C)

Department of Intensive Care Medicine and Infectious Diseases, Bichat-Claude Bernard University Hospital, AP-HP, 46 Rue Henri Huchard, 75877, Paris Cedex, France.
UMR 1137, IAME, Paris Diderot University, Paris, France.

C Sazio (C)

Medical Intensive Care Unit, Bordeaux University Hospital, Bordeaux, France.

M Conrad (M)

Medical Intensive Care Unit, Central Hospital, Nancy University Hospitals, Nancy, France.

V Susset (V)

Polyvalent Intensive Care Unit, Chambery Hospital, Chambery, France.

S Demeret (S)

Neurologic Intensive Care Unit, Pitié-Salpêtrière University Hospital, AP-HP, Paris, France.

J M Tadie (JM)

Medical Intensive Care Unit, Pontchaillou University Hospital, Rennes, France.

L Argaud (L)

Medical Intensive Care Unit, Edouard Herriot University Hospital, Lyon, France.

F Barbier (F)

Medical Intensive Care Unit, La Source Hospital, Orléans, France.

B Sarton (B)

Intensive Care Unit, Purpan University Hospital, Toulouse, France.

R Chabane (R)

Department of Perioperative Medicine, Clermont-Ferrand University Hospital, Clermont-Ferrand, France.

D Daubin (D)

Medical Intensive Care Unit, Montpellier University Hospital, Montpellier, France.

N Brulé (N)

Medical Intensive Care Unit, Nantes University Hospital, Nantes, France.

N Lerolle (N)

Medical Intensive Care Unit, CHU Angers, Angers University Hospital, Angers, France.

M Alves (M)

Polyvalent Intensive Care Unit, Poissy-Saint-Germain-en-Laye Hospital, Poissy, France.

D Da Silva (D)

Intensive Care Unit, Delafontaine Hospital, Saint-Denis, France.

A El Kalioubi (AE)

Medical Intensive Care Unit, Roger Salengro University Hospital, Lille, France.

S Silva (S)

Intensive Care Unit, Purpan University Hospital, Toulouse, France.

P Bailly (P)

Medical Intensive Care Unit, La Cavale Blanche University Hospital, Brest, France.

M Wolff (M)

Department of Intensive Care Medicine and Infectious Diseases, Bichat-Claude Bernard University Hospital, AP-HP, 46 Rue Henri Huchard, 75877, Paris Cedex, France.

L Bouadma (L)

Department of Intensive Care Medicine and Infectious Diseases, Bichat-Claude Bernard University Hospital, AP-HP, 46 Rue Henri Huchard, 75877, Paris Cedex, France.
UMR 1137, IAME, Paris Diderot University, Paris, France.

J F Timsit (JF)

Department of Intensive Care Medicine and Infectious Diseases, Bichat-Claude Bernard University Hospital, AP-HP, 46 Rue Henri Huchard, 75877, Paris Cedex, France.
UMR 1137, IAME, Paris Diderot University, Paris, France.

R Sonneville (R)

Department of Intensive Care Medicine and Infectious Diseases, Bichat-Claude Bernard University Hospital, AP-HP, 46 Rue Henri Huchard, 75877, Paris Cedex, France. romain.sonneville@aphp.fr.
UMR1148, LVTS, Sorbonne Paris Cité, Inserm/Paris Diderot University, Paris, France. romain.sonneville@aphp.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH